



LECTURE

Trophic factors for Parkinson's Disease: facts and dreams

Jose Martin Rabey¹

Special Issue on Controversies in Neurology. From the 10th World Congress on Controversies in Neurology (CONy), Lisbon, Portugal. 17–20 March 2016.

Abstract

Since the discovery of the trophic effects of nerve growth factor by Nobel laureate Rita Levi-Montalchini in the 1970's numerous studies have demonstrated that many trophic factors can prevent neuronal degeneration and increase the function of both intact and degenerating nerve cells. Moreover trophic factors show great promise in laboratory studies as potential therapies for PD. However multiple double—blind clinical trials have failed to show benefits in comparison to a placebo control.

With respect to developing a therapy for PD patients, the

GDNF family of ligands (GFLs) that include glial cell-derived neurotrophic factor (GDNF) and neurturin (NRTN) have received the most attention. Lin (1993) first discovered GDNF and demonstrated that it supports the viability of dopaminergic midbrain neurons in tissue culture. We will review in our presentation the scientific rationale for testing trophic factors in PD, the result of the different clinical trials that have been performed and the possible explanations for these failed outcomes. Future directions will be also considered.

¹Tel Aviv University, Israel

Citation: Rabey, JM. Trophic factors for Parkinson's Disease: facts and dreams. International Journal of Clinical Neurosciences and Mental Health 2016; 3(Suppl. 1):L20

Published: 16 March 2016



Open Access Publication Available at <http://ijcnmh.arc-publishing.org>

© 2016 Rabey, JM. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

